- Home
- ANEB vs NVNO Comparison
ANEB vs NVNO Comparison
Compare ANEB & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- NVNO
- Stock Information
- Founded
- ANEB 2020
- NVNO 1987
- Country
- ANEB United States
- NVNO United States
- Employees
- ANEB N/A
- NVNO N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- ANEB Health Care
- NVNO Health Care
- Exchange
- ANEB Nasdaq
- NVNO Nasdaq
- Market Cap
- ANEB 102.7M
- NVNO 96.0M
- IPO Year
- ANEB 2021
- NVNO N/A
- Fundamental
- Price
- ANEB $2.60
- NVNO $1.00
- Analyst Decision
- ANEB Buy
- NVNO
- Analyst Count
- ANEB 2
- NVNO 0
- Target Price
- ANEB $8.00
- NVNO N/A
- AVG Volume (30 Days)
- ANEB 142.0K
- NVNO 1.4M
- Earning Date
- ANEB 09-24-2025
- NVNO 07-31-2025
- Dividend Yield
- ANEB N/A
- NVNO N/A
- EPS Growth
- ANEB N/A
- NVNO N/A
- EPS
- ANEB N/A
- NVNO N/A
- Revenue
- ANEB N/A
- NVNO N/A
- Revenue This Year
- ANEB N/A
- NVNO N/A
- Revenue Next Year
- ANEB N/A
- NVNO N/A
- P/E Ratio
- ANEB N/A
- NVNO N/A
- Revenue Growth
- ANEB N/A
- NVNO N/A
- 52 Week Low
- ANEB $0.80
- NVNO $0.90
- 52 Week High
- ANEB $3.42
- NVNO $5.70
- Technical
- Relative Strength Index (RSI)
- ANEB 57.46
- NVNO 18.49
- Support Level
- ANEB $2.22
- NVNO $0.90
- Resistance Level
- ANEB $2.69
- NVNO $5.09
- Average True Range (ATR)
- ANEB 0.20
- NVNO 0.37
- MACD
- ANEB -0.04
- NVNO -0.46
- Stochastic Oscillator
- ANEB 65.52
- NVNO 2.36
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.